AXL and acute myeloid leukemia: Here, cabozantinib, a TKI used to treat medullary thyroid cancer and renal cell carcinoma by targeting tyrosine kinases c-Met, VEGFR2, and also AXL and RET, was repurposed to abrogate oncogenic FLT3 ITD activity in AML patients [111].